As of 2025-06-09, the Intrinsic Value of Alexion Pharmaceuticals Inc (ALXN) is 24.28 USD. This Alexion valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 182.50 USD, the upside of Alexion Pharmaceuticals Inc is -86.70%.
The range of the Intrinsic Value is 17.93 - 42.18 USD
Based on its market price of 182.50 USD and our intrinsic valuation, Alexion Pharmaceuticals Inc (ALXN) is overvalued by 86.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 17.93 - 42.18 | 24.28 | -86.7% |
| DCF (Growth 10y) | 31.91 - 82.58 | 45.21 | -75.2% |
| DCF (EBITDA 5y) | 51.84 - 73.84 | 63.15 | -65.4% |
| DCF (EBITDA 10y) | 60.88 - 97.73 | 78.33 | -57.1% |
| Fair Value | 64.16 - 64.16 | 64.16 | -64.84% |
| P/E | 30.84 - 65.14 | 48.54 | -73.4% |
| EV/EBITDA | 55.24 - 206.21 | 124.47 | -31.8% |
| EPV | 116.10 - 182.27 | 149.18 | -18.3% |
| DDM - Stable | 18.74 - 67.61 | 43.18 | -76.3% |
| DDM - Multi | 28.19 - 82.87 | 42.53 | -76.7% |
| Market Cap (mil) | 40,455.69 |
| Beta | 1.25 |
| Outstanding shares (mil) | 221.68 |
| Enterprise Value (mil) | 39,557.69 |
| Market risk premium | 4.24% |
| Cost of Equity | 8.11% |
| Cost of Debt | 4.25% |
| WACC | 7.84% |